New chief executive for Eyevensys
pharmafile | March 26, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Eyevensys
Gene therapy development firm Eyevensys has announced the appointment of Dr Ivan Cohen-Tanugi as chief executive.
Cohen-Tanugi has over 20 years’ experience in the international pharmaceutical industry, and will prepare the firm to launch clinical trials for the company’s non-viral gene therapy processes in two ophthalmic indications.
“I am delighted to have been given the responsibility of leading Eyevensys through to the next stages of its development,” said Cohen-Tanugi.
“Ivan Cohen-Tanugi’s extensive experience in the pharmaceutical and biotechnological fields will contribute to Eyevensys’ ability to move at a faster pace and proceed to the clinical phase in the best possible circumstances,” said professor Francine Behar-Cohen, Eyevensys’s founder and scientific advisor.
Before joining Eyevensys, Cohen-Tanugi was vice president and general manager of the Biologics and Specialty unit at Teva Pharmaceuticals in the US. He worked in Switzerland for many years for Roche Pharma, then for Amgen International and finally for Teva Pharmaceuticals. Cohen-Tanugi started his career at Sanofi, where he held various positions in France and the US.






